Severe Immune-Related Adverse Events Associated with Durable Antitumor Responses Following Immune Checkpoint Inhibitor Therapy: Two Case Reports
Qunxiang Chen, Xianglan Lin, Lingdan Chen, Juan Yao, Yun Yan, Xiaoyu Zhang, Dunya Yang, Xiangwu Lin, Shuyi Chen, Xi Chen, Naying Yu · 2026
Read Severe Immune-Related Adverse Events Associated with Durable Antitumor Responses Following Immune Checkpoint Inhibitor Therapy: Two Case Reports by Qunxiang Chen, Xianglan Lin, Lingdan Chen, Juan Yao, Yun Yan, Xiaoyu Zhang, Dunya Yang, Xiangwu Lin, Shuyi Chen, Xi Chen, Naying Yu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13570621.txt.
Description
Qunxiang Chen and co-authors present two case reports, published in 2026, on cancer patients who suffered severe side effects from immune therapy yet gained long-lasting control of their disease. Immune checkpoint drugs can unleash strong attacks on tumors, but they can also harm healthy organs. Past work hints that such side effects may go with better outcomes, though the link is uneven.
One patient with advanced breast cancer developed serious heart rhythm trouble and heart failure on the therapy. The other, with advanced lung cancer, developed hormone gland failure and skin harm. Both stopped all cancer treatment and were managed with steroid drugs. Even so, their tumors kept shrinking, with responses lasting twenty-two and thirty-seven months. The authors caution that side effects alone should not be read as proof a treatment is working.
Catalog record
| CREATOR | Qunxiang Chen, Xianglan Lin, Lingdan Chen, Juan Yao, Yun Yan, Xiaoyu Zhang, Dunya Yang, Xiangwu Lin, Shuyi Chen, Xi Chen, Naying Yu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |